BRAF and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, we describe here for the first time the unusual ability of the new compound SkE to inhibit B-Raf activation not only in melanoma and HCL but also in CML cell lines exhibiting constitutive activation of the ERK pathway.